During the past decade, Carolina Research Center, Inc. conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 6 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Carolina Research Center, Inc." #1 sponsor was "Pfizer" with 4 trials, followed by "Enanta Pharmaceuticals, Inc" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Carolina Research Center, Inc." #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator, "PPD" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Carolina Research Center, Inc." are "Chronic Obstructive Pulmonary Disease" (2 trials), "Diabetes Mellitus, Type 2" (2 trials), "Acute Pain" (1 trials), "Atopic Dermatitis" (1 trials) and "Back Muscle Spasm" (1 trials). Many other conditions were trialed in "Carolina Research Center, Inc." in a lesser frequency.

Most popular intervention types in "Carolina Research Center, Inc." are "Drug" (17 trials), "Other" (4 trials), "Behavioral" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Abrocitinib 200 mg" (2 trials), "Abrocitinib 100 mg" (1 trials), "Astegolimab" (1 trials) and "BHV-3500 (zavegepant)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Carolina Research Center, Inc." are 17 trials for "All" genders.

Currently, there are NaN active trials in "Carolina Research Center, Inc.". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Carolina Research Center, Inc., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Carolina Research Center, Inc., 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".